NBS >>> NeoStem (NYSE MKT: NBS) Positive Results of AMR-001 for Treatment of AMI
Wed 3:51 pm by Henry McCusker
New Publication That Supports Positive Results
NBS’ new article published by the International Scholarly Research Network provides … further evidence that AMR-001 appears capable of preserving heart muscle function following a large myocardial infarction.
Amorcyte demonstrated in its P1 trial that AMR-001 preserved heart muscle function when a therapeutic dose of cells was administered. No patient experienced deterioration in heart muscle function who received 10 million cells or more whereas 30 to 40 percent of patients not receiving a therapeutic dose did.
The article titled “Assessment of myocardial contractile function using global and segmental circumferential strain following intracoronary stem cell infusion after myocardial infarction: MRI Feature Tracking Feasibility Study” by Sabha Bhatti, MD, et al. appears in ISRN Radiology Volume 2013, Article ID371028 and is published online at http://www.isrn.com/journals/radiology/2013/371028.
The Bottom Line: The new study shows that cardiac muscle function sparing effects are evident even earlier after treatment than previously shown. AMR-001 improved blood flow to the heart and preserved heart muscle. By using cardiac magnetic resonance imaging, specifically measuring circumferential strain of the left ventricle, the authors show that AMR-001?s effects are evident by 3 months after STEMI.AMR-001?s angiogenic and anti-apoptotic mechanisms of action indicate that preservation of heart muscle function should start within weeks and be evident in fewer than 6 months. This publication, based on blinded analysis of Amorcyte’s P1 data, confirms the expected time course for AMR-001?s mechanism of action.
NBS NeoStem (NYSE MKT: NBS) Positive Results of AMR-001
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Vishay Intertechnology Announces Exciting Dividend Update
Vishay Intertechnology's Quarterly Dividend Announcement Vishay Intertechnology, Inc. (NYSE: VSH), a global leader in the manufacturing of discrete semiconductors and passive components, has recently made headlines by declaring a quarterly dividend. This announcement marks a significant moment for the company and its stakeholders as it reflects the steady financial health...
Continue Reading
Why Energy Brokerage Is One of the Most Overlooked Recession-Resistant Service Models
Most discussions about recession-resistant business categories focus on the obvious choices: healthcare, essential retail, waste management, and food. What rarely comes up, despite being one of the cleaner examples of a service with demand that genuinely does not shrink during economic downturns, is commercial energy management. Specifically, the energy brokerage model is...
Continue Reading
Stephens Ups Guaranty Bancshares Target to $40 with Positive Outlook
Stephens Upgrades Guaranty Bancshares' Price Target Recently, Stephens announced an increase in its target price for Guaranty Bancshares, Inc. (NYSE: GNTY) to $40.00. This updated estimation is an advancement from the previous target of $38.00. The positive adjustment comes after the company reported strong third-quarter earnings per share (EPS), which exceeded analysts'...
Continue Reading
Lightwave Logic Prepares for Special Call on March 13, 2025
Lightwave Logic's Upcoming Special Call Announcement Lightwave Logic, Inc. (NASDAQ: LWLG) has exciting news to share as it prepares to host a special call on March 13, 2025. This event aims to shed light on the industry applications of electro-optic polymers, the company’s competitive positioning, and its strategic approach to market penetration. What to Expect from the...
Continue Reading
Accelerating Oncology: ONCare Alliance and Ovation.io Team Up
Innovative Partnership Between ONCare Alliance and Ovation.io The ONCare Alliance and Ovation.io have embarked on an exciting collaboration to develop a multi-omics database and biobank aimed at accelerating biomarker discovery in the oncology field. This partnership combines the expertise of 32 independent oncology practices represented by ONCare with Ovation.io, a...
Continue Reading